Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 290,000 shares at $35.30 ($10.4M) on 2025-12-26, disclosed to the SEC on 2025-12-29.
Scheduled sale ($10.4M) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.21 | 75,117 | $2.7M | 26.2% |
| 2 | $36.21 | 75,117 | $2.7M | 26.2% |
| 3 | $35.68 | 26,011 | $928K | 8.9% |
| 4 | $35.68 | 26,011 | $928K | 8.9% |
| 5 | $35.30 | 43,872 | $1.5M | 14.9% |
| 6 | $35.30 | 43,872 |
| $1.5M |
| 14.9% |
| Total | $35.84 avg | 290,000 | $10.4M | 100% |
| Filing → |
| NAMS | SELL | 2026-05-27 | $2.3M | — | Filing → |
| NAMS | SELL | 2026-01-29 | $2.3M | — | Filing → |
| NAMS | SELL | 2026-01-27 | $2.4M | — | Filing → |